← board
INTI
distress 5/10 · elevated risk$0.080%today-39% from 52w high
Lead: Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome)
Revenue
pre-revenue
Liquidity
$1M
Runway
0.4 yrs
Shares 1y
0%
Price & events
-5.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-10.6%
1M
-15.6%
3M
-5.0%
6M
+38.2%
1Y
-11.6%
2Y
-68.5%
5Y
+105.4%
All
Overview
- Market Cap
- $13.12M
- Volume
- 0
- 52 Week Range
- $0.04 – $0.12
- Total Shares
- 172.57M
- Float Shares
- 77.56M
- Short %
- 0.36%
- % Held by Insiders
- 57.16%
- % Held by Institutions
- 0.00%
- Beta
- -0.78
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- on or about May 1, 2026 plasma samples shipped; bioanalysis ~2 weeks; statistical analysis ~2 weeksreadoutitraconazole · Top-line comparative PK and relative bioavailability results from crossover PK study in healthy subjects.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome)
- none identified
Recent news
- 2026-07-17FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
- 2026-06-28Enterprise value to EBITDA forward of Inhibitor Therapeutics Inc. – OTC:INTI - TradingView
- 2026-06-24Form 4 Inhibitor Therapeutics Inc For: 24 June By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.